Apyx Medical Corp (APYX)

NASD · Healthcare · Medical Devices · USA

Apyx Medical Corp is a micro cap company (market value under $300 million) in the Medical Devices industry.

Apyx Medical is a surgical aesthetics company offering Helium Plasma Platform Technology products including Renuvion and J-Plasma for cosmetic and hospital surgical markets, plus the AYON body contouring system. The company serves cosmetic surgeons through a direct sales force and international distributors, and manufactures products in Florida and Bulgaria.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Apyx Medical Corp stock.

Our verdict on APYX

Overvalued: intrinsic value $1.71 per share, market price $2.56, margin of safety -49.6% (as of 2026-11-17).

A 1.3x revenue multiple, discounted for its losses, values the shares at $1.71; the price of $2.56 is 50% above that value.

ETFs with the most weight in APYX

1 more funds hold it; the full list is part of the paid plan.

More on APYX

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than APYX in Medical Devices

29 more in this industry show a wider margin of safety.

Is APYX undervalued or overvalued?

APYX is overvalued (as of the 2026-11-17 close). A 1.3x revenue multiple, discounted for its losses, values the shares at $1.71; the price of $2.56 is 50% above that value.

What is the intrinsic value of APYX?

$1.71 per share (as of the 2026-11-17 close), against a market price of $2.56. That is a margin of safety of -49.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.